- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00761176
A Pilot Study of the Provant Therapy System in Subjects With Diabetic Foot Ulcers
A Controlled Study Comparing Basic Wound Care to the Provant® Therapy System as an Adjunct to Basic Wound Care for Wound Surface Area Reduction in Diabetic Plantar Foot Wounds
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
According to the American Diabetes Association (ADA), there are approximately 20.8 million people in the US with diabetes or 7% of the population (1). A significant number of the diabetic population is prone to pedal ulceration and estimates reveal that 15-20% of this population will develop a foot ulcer in their lifetime.
Treatment of diabetic foot ulcerations have posed a problem to healthcare providers for many years. The literature describes many different modalities for direct wound treatment strategies. Most of these treatments rely on the timely application of biological dressings, offloading of the wound, regular (and often inconvenient) visits to the doctor, and most important, compliance by the patient. It is not uncommon for such wounds to be present for greater than six months, despite use of debridement, off-loading and other basic wound care techniques, before presenting for advanced therapy.
Provant has been selected for study because:
- It is already indicated for the adjunctive palliative treatment of postoperative pain and edema in superficial soft tissue.
- It is a non-invasive wound treatment system which utilizes a proprietary PRFE signal which is hypothesized to trigger the release of endogenous growth factors that induce mitosis through accelerating the cell cycle, using a Ca+2 mediated pathway. The result is a significant increase in the rate of cell replication.
- It has also been shown that PRFE triggers a genetic sequence or cascade of 'wound repair' genes critical for the four stages of wound healing: inflammation, granulation, epithelialization, and remodeling.
- It has been utilized in the VA Health System since 2004 with no serious adverse events attributable to the device.
This study will assess as an endpoints:
- Primary - the incidence of wounds reaching complete closure, and
- Secondary - the time to complete wound closure percentage reduction in wound area, percentage reduction in wound volume, and rate of healing mm2/day and mm3/day.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston - Salem, North Carolina, United States, 27103
- Winston - Salem Outpatient Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females > 18 years of age
- History of Type 1 or 2 Diabetes Mellitus
- A diabetic plantar foot wound, Wagner grade 1 or 2 (See Exclusion Criteria, number four (4).
- The qualifying wound must have been present for ≥ 30 days; (the age of the wound will be recorded) based on patient history or documentation in the medical record.
- Ankle Brachial Index (ABI) score ≥ 0.7 and ≤ 1.2 with present palpable posterior tibial pulse or dorsalis pedis pulse in index foot
- Wound surface area ≥ 1.0 cm2 and ≤ 16.0 cm2
- Female subjects of childbearing age will be expected to test negative after taking a serum pregnancy test. Additionally, they must be willing to use an adequate and reliable method of contraception for the study duration. Females who are postmenopausal must have been postmenopausal at least one year or twelve months.
Exclusion Criteria:
- Glycosylated Hemoglobin (HbA1c) greater than 12 within 30 days of enrollment
- Absent pedal Doppler signals in the foot with the index wound or the presence of significant peripheral artery disease ,
- Concurrent treatment of the index wound with another advanced wound care device (i.e. negative pressure wound therapy, non-contact ultrasound, hyperbaric oxygen, electrical stimulation) or pharmaceutical (e.g. growth factors) within thirty (30) days of enrollment.
- Index wounds with exposed muscle, ligament or tendon, or which probe to bone regardless of classification-See Inclusion Criteria no. two ( 2).
- Wounds due to a nondiabetic etiology (e.g. venous stasis, arterial insufficiency, etc.)
- Cellulitis, osteomyelitis, or other clinical evidence of infection involving the index wound.
- History of malignancy
- Concurrent use of high dose immunosuppressant or cytotoxic drugs
- Implanted pacemaker or defibrillator
- Metallic implant involving the index foot or ankle
- Implanted system with a metallic lead
- Pregnant or lactating females
- Concurrent participation in another clinical trial. 14) An unwillingness of the patient to comply with the study procedures and the required follow-up regimen.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Standard of Care
Standard of Care will be utilized without the device.
|
|
Other: The Provant Therapy System
Thirty minutes, twice daily treatment
|
The Provant Wound Therapy System is a safe adjuvant non-invasive medical device.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Incidence of Wounds Reaching Complete Closure
Time Frame: approximate one year
|
approximate one year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mike Wilson, DPM, Winston - Salem Outpatient Clinic, WG Hefner VAMC
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RGI-08-08-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcers
-
CytomedixCTI Clinical Trial and Consulting ServicesTerminatedDiabetic Foot Ulcers | Wounds | Pressure Ulcers | Leg UlcersUnited States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada
-
HealthpointCompletedDiabetic Foot Ulcers (DFU) | Venous Stasis Ulcers (VSU)United States
-
Integra LifeSciences CorporationMayo Clinic; Temple University; Samuel Merritt University; New York College of... and other collaboratorsCompletedFoot Ulcers, DiabeticUnited States
-
Arteriocyte, Inc.TerminatedDiabetic Foot Ulcers | Pressure Ulcers | Venous UlcersUnited States
-
HealthpointCompletedDiabetic Foot Ulcers | Pressure UlcersUnited States
-
Oneness Biotech Co., Ltd.Completed
-
Hadassah Medical OrganizationUnknown
-
Systagenix Wound ManagementUnknownDiabetic Foot UlcersItaly, United States, United Kingdom, Germany, Spain
-
Southern California Institute for Research and...Heritage Medical Research InstituteUnknownDiabetic Foot UlcersUnited States
Clinical Trials on The Provant Therapy System
-
Regenesis Biomedical, Inc.CompletedDiabetic Neuropathy PeripheralUnited States
-
Regenesis Biomedical, Inc.CompletedDiabetic Peripheral NeuropathyUnited States
-
Southern California Institute for Research and...Regenesis Biomedical, Inc.Unknown
-
Regenesis Biomedical, Inc.CompletedOsteoarthritis, KneeUnited States
-
Regenesis Biomedical, Inc.Completed
-
Regenesis Biomedical, Inc.Completed
-
Regenesis Biomedical, Inc.WithdrawnPostoperative PainUnited States
-
Regenesis Biomedical, Inc.CompletedPost-Operative Pain Following Total Knee ArthroplastyUnited States
-
Regenesis Biomedical, Inc.Terminated
-
IRegained Inc.Laurentian University, Health Science NorthRecruitingStroke | Engagement, PatientCanada